| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2014PLoSO...9k5937C |
| P356 | DOI | 10.1371/JOURNAL.PONE.0115937 |
| P932 | PMC publication ID | 4280171 |
| P698 | PubMed publication ID | 25549252 |
| P5875 | ResearchGate publication ID | 270290732 |
| P50 | author | Travis Lear | Q55187835 |
| George D Leikauf | Q45733221 | ||
| P2093 | author name string | Alison C McKelvey | |
| Bill B Chen | |||
| Tiffany A Coon | |||
| Rahel L Birru | |||
| Nate M Weathington | |||
| P2860 | cites work | Lung pathology of fatal severe acute respiratory syndrome. | Q51670647 |
| Dual expression and differential regulation of phosphodiesterase 3A and phosphodiesterase 3B in human vascular smooth muscle: implications for phosphodiesterase 3 inhibition in human cardiovascular tissues | Q74045579 | ||
| Absorption and metabolism of cyanidin 3-O-beta-D-glucoside in rats | Q77780939 | ||
| Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system | Q24304493 | ||
| Insights into the regulation of TNF-alpha production in human mononuclear cells: the effects of non-specific phosphodiesterase inhibition | Q24648587 | ||
| Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules | Q27641962 | ||
| Cyclic nucleotide phosphodiesterases | Q28203598 | ||
| Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development | Q28242460 | ||
| Preparing for the next pandemic | Q28248583 | ||
| Viral pneumonia | Q28307886 | ||
| Targeting F box protein Fbxo3 to control cytokine-driven inflammation | Q28392009 | ||
| Innate immune response of human alveolar macrophages during influenza A infection | Q28731580 | ||
| Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms | Q29619683 | ||
| Elevated cyclic AMP and PDE4 inhibition induce chemokine expression in human monocyte-derived macrophages | Q33564601 | ||
| Antiplatelet therapy using cilostazol, a specific PDE3 inhibitor | Q33800110 | ||
| Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice | Q34006798 | ||
| Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships | Q34357867 | ||
| Discovery of novel PDE10 inhibitors by a robust homogeneous screening assay | Q34679687 | ||
| Historical insights into cytokines | Q34708047 | ||
| Role of PDE4 in superoxide anion generation through p44/42MAPK regulation: a cAMP and a PKA-independent mechanism. | Q35047671 | ||
| The influence of infection sites on development and mortality of ARDS. | Q35050455 | ||
| Phosphodiesterase 4B mediates extracellular signal-regulated kinase-dependent up-regulation of mucin MUC5AC protein by Streptococcus pneumoniae by inhibiting cAMP-protein kinase A-dependent MKP-1 phosphatase pathway | Q36080545 | ||
| ZINCPharmer: pharmacophore search of the ZINC database | Q36088378 | ||
| Roflumilast: a selective phosphodiesterase 4 inhibitor | Q36358921 | ||
| Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis | Q36757668 | ||
| A combinatorial F box protein directed pathway controls TRAF adaptor stability to regulate inflammation | Q36781352 | ||
| The future of the oral pharmacotherapy of male erectile dysfunction: things to come | Q36866594 | ||
| Cyclic AMP: master regulator of innate immune cell function. | Q37103511 | ||
| Phosphodiesterase 5 inhibition in essential hypertension | Q37119354 | ||
| Phosphodiesterase-4 inhibitor therapy for lung diseases | Q38105165 | ||
| The effect of oxidative stress on macrophages and lung epithelial cells: the role of phosphodiesterases 1 and 4. | Q40204025 | ||
| Cyclic nucleotide research -- still expanding after half a century | Q44123887 | ||
| Improvement of exercise capacity in monocrotaline-induced pulmonary hypertension by the phosphodiesterase-5 inhibitor Vardenafil | Q45111162 | ||
| Comparative relaxing effects of sildenafil, vardenafil, and tadalafil in human corpus cavernosum: contribution of endogenous nitric oxide release. | Q45178889 | ||
| Absorption and metabolism of cyanidin-3-glucoside and cyanidin-3-rutinoside extracted from wild mulberry (Morus nigra L.) in rats. | Q46197858 | ||
| Lignans from the Fruits of Forsythia suspensa (Thunb.) Vahl Protect High-Density Lipoprotein during Oxidative Stress | Q46329016 | ||
| Evidence for a role of phosphodiesterase 4 in lipopolysaccharide-stimulated prostaglandin E2 production and matrix metalloproteinase-9 activity in human amniochorionic membranes. | Q46535464 | ||
| Preparative isolation and purification of phillyrin from the medicinal plant Forsythia suspensa by high-speed counter-current chromatography | Q46633155 | ||
| Lignans from the fruits of Forsythia suspensa | Q46737196 | ||
| Antioxidant and antibacterial activity of two compounds (forsythiaside and forsythin) isolated from Forsythia suspensa | Q46780457 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e115937 | |
| P577 | publication date | 2014-12-30 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Novel PDE4 inhibitors derived from Chinese medicine forsythia | |
| P478 | volume | 9 |
| Q50599475 | Effects of meglumine cyclic adenylate pretreatment on systemic inflammatory response syndrome induced by lipopolysaccharide in rats. |
| Q47569732 | Forsythiae Fructus: A Review on its Phytochemistry, Quality Control, Pharmacology and Pharmacokinetics |
| Q99200887 | Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-κB) signaling pathway |
Search more.